Molecular Diagnostics VL

Count Me In! The Metastatic Prostate Cancer Project - Eliezer Van Allen

Eli Van Allen shares details on The Metastatic Prostate Cancer Project, a project part of a larger nationwide genomic research project called "Count Me In" for men with advanced or metastatic prostate cancer. The Metastatic Prostate Cancer Project takes a new approach to cancer research in which researchers partner directly with men with metastatic and/or advanced prostate cancer, who share their...

Genetic Risk in Prostate Cancer - Jacob Berchuck & Mary-Ellen Taplin

Jacob Berchuck, MD and Mary-Ellen Taplin, MD join Alicia Morgans in discussing areas of genetic risk in high-risk localized prostate cancer. They discuss the complexity of screening patients and incorporating the identifying of patients for genetic risk into clinical workflow. Jacob shares details on a collaboration with Mark Pomerantz at Dana-Farber and Phil Kantoff at Memorial Sloan Kettering, a...

The Association of PBAF Complex Mutations with Overall Survival in Cancer Patients Treated with Checkpoint Inhibitors - Sarah Abou Alaiwi

Sarah Abou Alawi, MD discusses her recently presented bench to bedside research with Monty Pal, MD. She explains that PBRM1 is frequently mutated around 40% on Renal Cell Carcinoma. It is part of this Mammalian SWI/SNF complex, which is really what drove interest in this complex. This complex is really huge. It has 29 subunits. It's frequently mutated in around 20% of all human cancers. There is p...

Genetic Counseling in Prostate Cancer - Brittany Szymaniak

Alicia Morgans discusses genetic counseling in GU cancers with Brittany Szymaniak. This conversation includes the challenges, the benefits, the concerns of genetic testing and how this is accomplished in clinical practice for people who have genital urinary malignancies, so prostate cancer, bladder cancer, kidney cancer. They also discuss the family syndromes for men with prostate cancer that shou...

Molecular Genetic Testing in Prostate Cancer - Wassim Abida

Wassim Abida provides a current roadmap for molecular genetic subtyping in prostate cancer with the main goal of targeting the right therapies for progressing patients. The one clear indication for molecular testing at this point is in the identification of MSI-high prostate cancer because pembrolizumab is approved for this indication. Investigational PARP inhibitors (poly (ADP-ribose) polymerase...

Influence of BRCA-2 Mutations on the Natural History and Response to Therapy in Prostate Cancer- Elena Castro

Elena Castro, MD discusses the role of BRCA-2 mutations and the risk of developing prostate cancer. BRCA-2 germline carriers have an increased risk of developing prostate cancer representing a ~30% lifetime rate of developing prostate cancer. Patients with BRCA-2 mutations tend to develop more aggressive prostate cancer and typically present with lymph node involvement or distant metastases. Based...

DNA Repair Defects in Metastatic Prostate Cancer - Elena Castro

Elena Castro, MD discusses her recent publication in Journal Clinical Oncology on DNA repair defects in prostate cancer. The primary objective of the study was to determine whether mutations in BRCA 1, BRCA 2, ATM and PALB 2 would affect survival in patients diagnosed with mCRPC. A panel of 107 genes was analyzed. Patients who were carrying these mutations, in particular, BRCA2, had shorter surviv...

Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) A Phase II Study - Emmanuel Antonarakis

Emmanuel Antonarakis introduces the Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH). The aim of this Phase II clinical trial is to find out if the study drug rucaparib leads to lowering of PSA levels in men with metastatic prostate cancer that has not yet been treated with androgen deprivation therapy (also ref...

TRIUMPH Study: Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations - Mark Markowski

(Length of Discussion: 12 min) Alicia Morgans discusses with Mark Markowski details of the TRIUMPH trial, a single-arm, phase II trial, open-label using a PARP inhibitor rucaparib, in the absence of androgen deprivation therapy in men with metastatic hormone-naive prostate cancer. Biographies: Mark Christopher Markowski, MD., Ph.D., is a medical oncologist at the Kimmel Cancer Center at Sibley Mem...

The Role of the PARP Inhibitor in Treating Prostate Cancer: Interview with Joaquin Mateo

Alicia Morgans and Joaquin Mateo discuss mapping the genomic landscape of advanced prostate cancer, and the realization that many patients with advanced forms of prostate cancer have tumors with defects in the repair of DNA damage. And what we observed for the first time is actually that a drug like olaparib, a PARP inhibitor, that has been used in breast or ovarian cancer, were associated to thes...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.